uniQure (NASDAQ: QURE)
You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
uniQure Returns vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
uniQure Company Info
uniQure N.V.
News & Analysis
A big approval for a gene therapy sent the biotech's stock higher.
The company is temporarily delaying higher-dose procedures of experimental gene therapy AMT-130.
It just reported a packet of promising safety data for its flagship pipeline program.
Several drugmakers have important clinical trial updates on the way.
A clinical hold is weighing on the biotech's shares today.
Agreement licenses the rights for a promising hemophilia B gene therapy.
Here are the biotechs most likely to receive juicy buyout offers in 2020.
Investor optimism is surging following recent M&A in gene therapy.
Motley Fool Returns
Market-beating stocks from our award-winning analyst team.
Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 02/01/2023.
Discounted offers are only available to new members. Stock Advisor list price is $199 per year.
Calculated by Time-Weighted Return since 2002. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.